Loading...
XNASREVB
Market cap2mUSD
Dec 24, Last price  
0.31USD
1D
3.47%
1Q
-58.89%
IPO
-100.00%
Name

Revelation Biosciences Inc

Chart & Performance

D1W1MN
XNAS:REVB chart
P/E
P/S
EPS
Div Yield, %
0.00%
Shrs. gr., 5y
Rev. gr., 5y
%
Revenues
0k
Net income
-120k
L-98.89%
-3,638-1,630,500-11,986,837-10,794,587-120,254
CFO
-7m
L-35.06%
0-215,074-11,090,573-11,219,396-7,286,286
Earnings
Mar 20, 2025

Profile

Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. The company engages in developing therapeutic product candidates, including REVTx-99b that is in a Phase Ib clinical trial for the prevention or treatment of chronic nasal congestion and allergic rhinitis; and REVTx-200, a nonclinical stage product for intranasal therapy. It is also involved in developing REVTx-300, a non-clinical stage product that is being developed as a potential therapy for the treatment of chronic organ disease, including chronic kidney disease and non-alcoholic steatohepatitis; and REVDx-501, a rapid test kit, which is a point of care in vitro diagnostic test that has the potential to detect respiratory viral infections, such as SARS-CoV-2, Influenza A, Influenza B, parainfluenza, or respiratory syncytial virus. The company was founded in 2020 and is based in San Diego, California.
IPO date
Oct 08, 2020
Employees
6
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑12
Income
Revenues
Cost of revenue
8,682
10,905
12,020
Unusual Expense (Income)
NOPBT
(8,682)
(10,905)
(12,020)
NOPBT Margin
Operating Taxes
(35)
(220)
Tax Rate
NOPAT
(8,682)
(10,870)
(11,800)
Net income
(120)
-98.89%
(10,795)
-9.95%
(11,987)
635.16%
Dividends
Dividend yield
Proceeds from repurchase of equity
14,025
(3,191)
8,005
BB yield
-12,251.00%
89.07%
-6.06%
Debt
Debt current
(2,911)
17
Long-term debt
17
Deferred revenue
Other long-term liabilities
554
2,911
Net debt
(11,992)
(8,164)
(1,241)
Cash flow
Cash from operating activities
(7,286)
(11,219)
(11,091)
CAPEX
(4)
(132)
Cash from investing activities
(132)
Cash from financing activities
14,025
15,198
8,005
FCF
(10,693)
(9,006)
(11,717)
Balance
Cash
11,992
5,253
1,275
Long term investments
Excess cash
11,992
5,253
1,275
Stockholders' equity
(25,467)
(25,346)
(7,033)
Invested Capital
32,115
23,487
6,950
ROIC
ROCE
586.64%
14,530.88%
EV
Common stock shares outstanding
229
538
370
Price
0.50
-92.47%
6.65
-98.14%
357.00
1.49%
Market cap
114
-96.80%
3,583
-97.29%
132,031
 
EV
(11,877)
(4,581)
138,271
EBITDA
(8,657)
(10,879)
(12,003)
EV/EBITDA
1.37
0.42
Interest
35
42
Interest/NOPBT